Elsamany, S.A. (2025) “Neoadjuvant Chemotherapy Plus Denosumab Compared to Chemotherapy Alone in Hormonal Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Premenopausal Breast Cancer Patients”, World Journal of Oncology, 16(5), pp. 502–508. doi:10.14740/wjon2546.